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Summary
Summary: A proportion of patients undergoing epilepsy surgery, and receiving car-
bamazepine (CBZ), experience significant elevations in CBZ plasma concentrations,
some with associated CBZ toxicity. The objective of this study was to identify
significant risk factors for elevations (>12 mg/ml) in CBZ concentrations and CBZ-
induced toxicity following epilepsy surgery.
Methods: We retrospectively examined charts of 74 inpatients (31 children and 43
adults) chronically receiving CBZ and undergoing epilepsy surgery between January
1996 and June 2000. Patient demographics, medications, type of surgery, seizure
history, adverse events, CBZ doses and concentrations were evaluated.
Results: 51.2% of adults and 51.6% of pediatric patients had drug elevations. In the
pediatric group, 12.9% had symptoms of toxicity compared to 9.3% in the adult group.
Five risk factors–—pre-operative CBZ dose, fentanyl dose, surgery day CBZ concen-
tration, body weight, and blood loss–—were related to post-operative CBZ concentra-
tions. Three risk factors: age <18 years, pre-operative CBZ dose, and the surgery day
CBZ (immediate pre-operative) concentration, were significantly related to the
outcome measure of abnormal CBZ concentration (>12 mg/ml). Two variables sig-
nificantly related to toxicity were average post-operative CBZ dose and the surgery
day CBZ concentration. Increases in concentrations occurred at a mean 33  13.7 h
(range: 11—74 h) after surgery.
Discussion: Based upon our results in patients with one or more risk factors, we
suggest that reduction of post-operative CBZ doses be considered.
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Carbamazepine (CBZ) is an anticonvulsant com-
monly used in the treatment of both generalized
and partial-onset seizures.1 CBZ is considered the
drug of choice for patients suffering from partial
seizures; as a result, CBZ is used in many epilepsy
surgery patients.
CBZ is unique among anticonvulsants, in that it
induces its own hepatic metabolism (i.e., autoin-
duction). This process occurs over the 1st month of
therapy with steady state clearance rates being
reached after this time. After autoinduction is com-
plete, CBZ reaches steady-state plasma concentra-
tions within 4 days of therapy.1 Average therapeutic
plasma concentrations of the drug range from 4 to
12 mg/ml. The drug has a relatively long half-life,
with a range of 8—72 h.1 The cytochrome P450 3A4
enzyme (CYP3A4) converts CBZ to its active meta-
bolite, CBZ 10,11-epoxide.1
Investigators have noticed that some individuals
who are on CBZ therapy, and who undergo epilepsy
surgery, have elevations of carbamazepine serum
concentrations during the post-operative period.
Some individuals with elevations of drug concentra-
tions have developed symptoms of carbamazepine
toxicity. We are not aware of elevations in the
concentrations of other anti-epileptic medications
during the post-operative period.
Cruz-Rodriguez and others were one of the first to
describe this phenomenon in a group of patients
undergoing epilepsy surgery, in 1989.2 This study
evaluated 32 patients who were on CBZ therapy, and
who underwent corpus callosotomy, temporal
lobectomy, or subdural grid placement for seizures.2
CBZ concentrations reached a maximum value on
the 4th post-operative day.2 Further, this elevation
in CBZ concentrations was 25% higher than base-
line.2
A case report by Wright and others described
post-operative carbamazepine toxicity in a patient
who underwent cardiothoracic surgery.3 The report
described a patient who had elevation of CBZ to
21.5 mg/ml on the 2nd post-operative day from pre-
operative steady-state concentrations that ranged
from 6.6 to 9.3 mg/ml, and who suffered symptoms
of CBZ toxicity, such as lethargy, diplopia, dysar-
thria, and nystagmus.3
Gidal and others studied CBZ metabolites such as
CBZ 10,11-epoxide, and the drug-binding protein,
a1-acid glycoprotein, during the pre- and post-
operative period.4 The authors concluded that
CBZ and CBZ 10,11-epoxide concentrations increase
during the post-operative period in some patients,
but such elevation was not the result of alterations
in serum drug-binding to plasma proteins.4To date, no study has elucidated the cause of CBZ
elevation and toxicity during the post-operative
period. However, as a result of these previous stu-
dies, it is evident that a certain percentage of the
population will have elevations of CBZ concentra-
tions during the post-operative period, and some of
these individuals will go on to develop symptoms of
carbamazepine toxicity.
Our objective in this study was to identify risk
factors for elevations in CBZ concentrations, and
CBZ-induced toxicity following epilepsy surgery. In
addition, we believed that fentanyl, an analgesic
that is commonly administered during the intrao-
perative period,may be involved in CBZ elevation. It
became evident from recent studies such as one by
Hase, Oda and others, that fentanyl may inhibit the
CYP3A family of hepatic enzymes.5 Hase and cow-
orkers evaluated the relation between fentanyl, and
its effect on the drug midazolam, which is metabo-
lized by CYP3A.5 Patients who received fentanyl
during the intraoperative period had higher post-
operative concentrations of midazolam, compared
to patients who did not receive fentanyl (placebo
group).5 Through such inhibition of the CYP3A family
of enzymes, and possibly CYP3A4, fentanyl may
likewise, cause an elevation of CBZ concentrations
during the post-operative period by preventing CBZ
metabolism.Methods
We reviewed 336 patients who underwent some
form of epilepsy surgery between January 1996
and June 2000. To be included in the study, patients
had to have been on a stable dose of CBZ for greater
than 1 month prior to the date of surgery. Patients
who underwent subdural grid placement for map-
ping of seizure foci were not included in the study
because these patients either had their antiepilep-
tic medication reduced, or discontinued during the
post-operative period. We found that 74 patients
met these criteria, and were therefore included in
our study group. Of these 74 patients, 31 were
children (<18 years) and 43 were adults.
The mean age of the pediatric group was 10.8
years, and the median age was 12 years. The age
range was from 0.25 to 17 years. Eleven out of 31
patients in the pediatric group were adolescents
(13 years of age).
Once patients were included in the study, a thor-
ough review of the medical records was undertaken
for each patient. The following demographic infor-
mation was obtained: age, race (white or non-
white), sex (male or female), and weight. Also
evaluated were the seizure etiology and history,
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patient underwent. The details of the intraopera-
tive course, such as blood loss, duration of anesthe-
sia, duration of surgery, and the total fentanyl dose
administered were examined.
In addition, each patient’s medication history,
including medications and dosages received during
the intra- and post-operative period was verified
through the medication administration records.
These included, but were not limited to, other
anesthetic medications administered during the
intraoperative period, and other medications such
as other antiepileptic drugs during the post-opera-
tive period.
We evaluated the pre- and post-operative CBZ
doses and CBZ concentrations. Three risk factors,
pre-operative CBZ dose, post-operative CBZ dose,
and fentanyl dose, were standardized to body
weight (dose/body weight). Some patients did not
have CBZ concentrations drawn during the immedi-
ate pre-operative period (<24 h prior to surgery)–—
in this case, these patients’ last CBZ concentration
prior to surgery was obtained from medical records.
Patients who did not have a CBZ concentration
drawn within 6 months before the date of surgery
were excluded from the study. There were seven
patients who were included in the study with levels
that were higher than normal. None of these
patients suffered from symptoms of CBZ toxicity
during the pre-operative period. Post-operative
CBZ concentrations were drawn on the morning
after surgery, and every morning thereafter until
the patient was discharged from hospital.
Finally, a thorough review of the patient’s post-
operative course using the physicians’ orders, pro-
gress notes, and nursing records was undertaken to
find patients who suffered from CBZ toxicity during
this period. The exact times at which CBZ concentra-
tions were drawn were also documented. All CBZ
concentrationswere at trough. Allmedications admi-
nistered to the patient in the post-operative period
were evaluated, and patients on medications known
to cause interactions with CBZ were excluded. Spe-
cifically, patients who were given propoxyphene–—a
component of the frequently used post-operative
analgesic Darvocet1–—were excluded from the study.
CBZ toxicity was divided into three groups–—mild,
moderate, and severe. Mild toxicity was defined as
nystagmus, diplopia, intention tremor, lethargy, and
blurred vision. Severe CBZ toxicity was defined as
altered consciousness, namely stupor and coma.
Moderate toxicity was initially defined as ataxia,
nausea, and vomiting. However, we were not able to
differentiate nausea and vomiting resulting from
the post-operative state, versus secondary to CBZ
toxicity. Therefore, moderate CBZ toxicity wasredefined as ataxia. Nursing notes and physician
progress notes were thoroughly evaluated for symp-
toms of CBZ toxicity–—specifically, careful attention
was paid to the presence of the characteristic neu-
rological manifestations of CBZ toxicity.
Three outcome measures were evaluated. These
were abnormal CBZ concentration, post-operative
CBZ concentration, and the presence of CBZ toxicity
symptoms. The difference between the first two
outcome measures can be viewed as being a linear
versus binary one. Abnormal CBZ concentration is a
binary outcome measure. The CBZ concentration
was either greater than 12 mg/ml, or it was within
normal limits. Post-operative CBZ concentration is a
linear measure. Only the magnitude of the CBZ
concentration changes during the post-operative
period was taken into consideration here.
In addition, a repeated measures ANOVA was
performed to evaluate which variables were asso-
ciated with all CBZ measurements (including pre-
operative), and to determine which variables were
significantly related to the rate of CBZ change both
pre- and post-operatively (by including interactions
with time post-surgery). Compound symmetry cov-
ariance methods were used, and only day 0 to day 4
post-surgery were used because of sparseness of CBZ
measures beyond day 4.
Risk factors were evaluated using a stepwise
multivariate logistic regression for binary variables
such as abnormal CBZ concentration, and presence
of CBZ toxicity symptoms. Risk factors were eval-
uated using a stepwise multiple linear regression for
the continuous variable, CBZ concentration. Signif-
icance was defined at p < 0.05 using two-tailed
tests. Odds ratios were calculated for the increase
or decrease in odds of toxicity or abnormal CBZ
concentration with the risk factor at hand. Calcula-
tions were performed with SAS version 8 software
(SAS Institute Inc., Cary, NC, USA).Results
With regards to age, 42% were children, and 58%
were adults; 86% of our study group was white, 14%
were non-white; 45% of our study group was male,
and 55% were female. Age, race, and sex were
evaluated as possible risk factors. Age, race or
sex was not associated significantly with any of
our three outcome measures.
51.6% of the pediatric group, and 51.2% of the
adult group in our study had elevated CBZ concen-
trations during the post-operative period. 12.9% of
the pediatric group, and 9.3% of the adult group had
CBZ toxicity during the post-operative period. Five
patients suffered from symptoms of moderate CBZ
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Table 1 Significant factors associated with post-sur-
gery CBZ concentrations.
Risk factor Regression
estimatea
p-Value
Surgery day CBZ
concentration
0.422 <0.0001
Preop CBZ dose/weight 0.178 <0.0001
Weight 0.049 <0.0001
Fentanyl dose/weight 0.145 0.02
Blood loss 0.00292 0.03
a Regression estimates of effect on CBZ concentrations for
each increase of 1 mcg of fentanyl/kg, 1 unit of pre-operative
CBZ dose/kg, 1 unit of surgery day CBZ concentrations, 1 kg of
body weight, and 1 unit of blood loss.toxicity; three patients suffered symptoms of mild
CBZ toxicity. The differences between the two
groups with regards to the proportion of individuals
affected were not significant for either the outcome
measure of elevated CBZ concentration or CBZ toxi-
city. Of the seven patients with abnormally high pre-
operative CBZ concentrations, six continued to have
abnormally high post-operative CBZ concentrations.
Two of the seven patients developed mild CBZ toxi-
city during the post-operative period.
The five significant factors related to post-opera-
tive CBZ concentrationswerepre-operative CBZdose
(mg/kg), fentanyl dose (mg/kg), surgery day CBZ
concentrations (mg/L), body weight (kg), and blood
loss (ml). Increasing concentrations of all of these
variables were associated with increasing CBZ con-
centrations, except blood loss. Increasing amounts of
blood loss–—approximately 100 ml up to maximal
amounts of 300 ml–—were related to decreasing
CBZ concentrations post-operatively (Table 1).
As Table 2 shows, three risk factors were signifi-
cantly related to the outcome measure of abnormal
CBZ concentration (>12 mg/ml). These risk factors
included age, pre-operative CBZ dose, and the sur-
gery day CBZ concentration–—the CBZ concentration
on the morning of surgery. The relationship between
these risk factors and this outcome measure was a
very significant one (Table 2).Table 2 Significant factors associated with abnormal
CBZ > 12.
Risk factor Odds ratioa p-Value
Age 1.037 0.001
Pre-operative CBZ dose/weight 1.107 <0.0001
Surgery day CBZ concentrations 1.464 <0.0001
a Increased odds of subject having an abnormal CBZ con-
centration for every 1 unit increase in age (years), 1 unit
increase in pre-operative CBZ dose (mg/kg), or 1 unit increase
in surgery day CBZ concentration (mg/ml).Repeated measures ANOVA was used to evaluate
risk factors related to multiple CBZ measures taken
from day 0 to day 4 post-surgery. Only pre-operative
CBZ dose (mg/kg) (p < 0.0001) and day post-surgery
(p < 0.0001) were significantly related to CBZ mea-
sures. The significance of day post-surgery indicates
that, on average (S.E.), CBZ concentrations
increased 0.77  0.12 mg/ml per day. There were
no significant interactions with post-surgery day,
indicating that there was no significant difference
in the rate of CBZ change based on baseline char-
acteristics.
The two variables significantly related to toxicity
were average post-operative CBZ dose (mg/kg) and
the CBZ concentration on the day of the surgery,
which was measured on the morning of the surgery.
The mean CBZ concentration in patients without
symptoms of toxicity was 8.8 mg/ml, and 10.2 mg/
ml in patients with symptoms of toxicity. CBZ toxi-
city was significantly related to a post-operative CBZ
dose greater than 6.1 mg/kg (Table 3).
Surgery day CBZ concentration was the only sig-
nificant risk factor that was related to all of the
three outcome measures–—post-operative CBZ con-
centrations, abnormal CBZ concentrations, and
toxicity.
Twenty-four percent (18/74) of patients had an
absolute elevation of CBZ concentration of greater
than 10 mg/ml. The highest absolute increase of CBZ
concentration in a patient was 13.4 mg/ml. Nine
percent (7/74 patients) of patients had a reduction
in their post-operative CBZ concentration from the
pre-operative state. A higher pre-operative CBZ
concentration was not related to a higher absolute
increase in post-operative CBZ concentration. The
correlation coefficient between these two variables
was 0.32.
Increases in CBZ concentrations occurred at a
mean of 33  13.7 h after surgery, with a range of
11—74 h. CBZ toxicity occurred at a mean of
18.5  13.4 h after surgery. The mean CBZ concen-
tration at which time toxicity symptoms were noted
was 12.5  4.5 mg/ml, with a range of 6.2—19.6 mg/
ml. Most individuals who had drug elevations during
the post-operative period did so by the 3rd post-
operative day, or 72 h post-operatively. The median
time for the first CBZ concentration greater thanTable 3 Significant factors associated with toxicity.
Risk factor Odds ratioa p-Value
Surgery day CBZ concentration 1.551 0.001
Post daily dose/weight 1.193 0.005
a Increased odds of subject having CBZ toxicity for every
1 unit increase in surgery day CBZ concentration (mg/ml) or
post-operative CBZ dose (mg/kg).
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had CBZ drug elevations to the abnormal range did
so by 44 h after surgery.Discussion
A high pre-operative (surgery day) CBZ concentra-
tion was the only risk factor that directly correlated
with all the three outcome measures that were
evaluated. As a result, we believe that individuals
who undergo epilepsy surgery should have pre-
operative (surgery day) CBZ concentrations checked.
With regard to fentanyl dose, a significant
( p < 0.05) relationship was found with increasing
fentanyl dose, which correlated directly with
increased post-operative CBZ concentrations. It
appears that fentanyl causes inhibition of the
CYP450 enzyme, especially CYP3A, as reported by
Hase et al.4 in 1997. CYP3A is also the enzyme that
metabolizes CBZ. Therefore, it is possible that inhi-
bition of the enzyme would cause decreased meta-
bolism of CBZ. Nevertheless, this phenomenon must
be further studied before recommendations regard-
ing the use of fentanyl in the intraoperative period
are made. That is, a prospective study that employs
the above guidelines, and which compares the use of
fentanyl to a control group, would further support
such a relationship.
Increasing body weight tended to protect against
CBZ elevation. We feel it is important to recognize
the increased likelihood of developing CBZ elevation
in people with lower body weight, especially chil-
dren. Although not evaluated in our study, the
ability to metabolize CBZmay be directly associated
with calculated liver size based on height and
weight measurements.6
We analyzed age as a variable independent of
body weight and found it to be significantly asso-
ciated with elevated post-operative CBZ concentra-
tions >12 ug/ml. It is unclear how age is related to
abnormal CBZ concentrations, but may have to do
with the increased rate of metabolism of CBZ in
children compared with adults.1Table 4 CBZ pre- and post-operative doses as risk factors
Variable
Pre-operative dose (mg/kg)
Post-operative dose (mg/kg)
Fentanyl dose (mg/kg)
Pre-operative surgery day CBZ concentration (mg/ml)
Body weight (kg)
a 50th percentile of the range of pre- and post-operative doses cAnother risk factor was decreasing amounts of
blood loss, which tended to correlate with increased
CBZ concentrations post-operatively. This relation-
ship ( p = 0.03) is not as strong as the relationship
with the other risk factors, albeit a significant one.
There is especially more skepticism regarding this
variable and its relationship because blood loss
during all of the surgeries were estimated, and some
surgeries did not record blood loss, or mentioned
blood loss as being ‘‘minimal.’’ Again, the impact of
blood loss needs to be further examined.
Other factors that are inherent during the post-
operative period include inflammatory changes,
especially the release of cytokines, and other
immune modulators. It is possible that these sub-
stances may alter the pharmacokinetics of CBZ
during the post-operative state. However, since
all patients in our study were evaluated during
the post-operative state, and the duration of each
surgery was taken into account–—and proved to not
be a significant factor in our results–—it is unclear
how important such substances were in the deter-
mination of CBZ concentrations during the post-
operative period in our study.
We recommend that post-operative CBZ concen-
trations be measured every 12 h for the first 72 h of
the post-operative period in patients who have one
or more risk factors for CBZ elevation or toxicity
because we noted that a majority of these patients
developed CBZ elevation or toxicity during this
time. The number of patients in this group devel-
oping either CBZ elevation or toxicity began to level
off around 48 h after surgery. All other individuals
with no risk factors should have CBZ concentrations
checked at least every 24 h for the first 72 h of the
post-operative period (Table 4).
Because of the well-established direct correla-
tion between CBZ dose and CBZ concentration, we
suggest that consideration be given to post-opera-
tive CBZ dose reduction by approximately 30% in
patients who have one or more risk factors for CBZ
elevation or toxicity. The reduced dose should be
maintained during the initial 3—5 days after surgery.
As illustrated in the above table, the median mg/kgfor CBZ elevation and toxicity.
Mediana
(all patients)
Mediana
(pediatric group)
Mediana
(adult group)
17.8 21.0 16.0
17.6 18.8 16.5
4.5
9.25
67
orrected for weight.
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Figure 1 Percentage of patients with abnormal CBZ
concentrations vs. number of risk factors.dose in the pediatric group tended to be higher than
in the adult group, therefore management guide-
lines must reflect the observed differences among
the age groups. Specifically, we recommend that
CBZ dose reduction be considered in: Pediatric patients with a pre-operative dose
>21.0 mg/kg or a post-operative CBZ dose
>18.8 mg/kg. Adults with a pre-operative CBZ dose >16mg/kg
or a post-operative CBZ dose >16.5 mg/kg. All patients treated with CBZ and who have the
following:
- Fentanyl cumulative dose greater than 4.5 mg/
kg.- Surgery day CBZ concentration >9.25 mg/ml.
- Total body weight <67 kg.The reduced dose should be monitored during the
initial 3—5 days after surgery. Such individuals sh-
ould be closely monitored, and if possible, attempts
should be made to modify these risk factors (Fig. 1).
We recognize, however, that in some patients,
CBZ dose reduction may lead to increased seizures.
In these cases, the clinician should use appropriate
clinical judgment. In this situation, if CBZ dosage is
not reduced, CBZ concentrations should be moni-
tored closely during the immediate post-operative
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